{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:25:03Z","timestamp":1777983903842,"version":"3.51.4"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Crush syndrome (consisting of hyperkalemia, acidosis, hypocalcemia, and acute kidney injury), is the second-most common cause of death in earthquakes, and a frequent cause of critical illness after burn, blast, and prolonged immobility. No specific treatment exists; supportive treatment is burdensome, contributing to deaths in austere environments, especially disasters and conflicts. There is urgent need for specific treatment which reduces burden of care. Crush syndrome is dependent on the renal megalin-dependent endocytic system. We investigated whether cilastatin sodium, a megalin inhibitor which is US Food and Drug Administration-approved for another purpose, has efficacy as a crush syndrome treatment in a highly translational large animal trauma model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Anesthetized 40\u2009kg female pigs received blunt muscle injury and 48\u2009h protocolized critical care management. Cilastatin sodium or vehicle was administered 30\u2009minutes after injury in randomized, blinded fashion. Renal function and injury were assessed by repeated quantification of iohexol clearance, serial plasma assessment, and histopathologic analysis. Linear mixed models and Kaplan-Meier analysis were used to assess differences. A power estimate for a clinical trial was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here we show that cilastatin has efficacy to reduce kidney impairment from crush syndrome, resulting in increased measured glomerular filtration rate and reduced creatinine, histopathologic kidney damage, and need for treatment of hyperkalemia. Animals receiving cilastatin excrete more myoglobin in the urine and are more likely to recover from acute kidney injury. The effect size suggests feasibility of future clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cilastatin sodium has efficacy to ameliorate crush syndrome in a translational large animal model These results support further efforts to translate this potential therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-026-01411-1","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:54:41Z","timestamp":1773312881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of cilastatin sodium in a translational large animal crush syndrome model"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1960-5486","authenticated-orcid":false,"given":"Adam C.","family":"Munhall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahaba B.","family":"Eiwaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica F.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahnee","family":"Groat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole K.","family":"Andeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Muruve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6653-875X","authenticated-orcid":false,"given":"Ian J.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Loss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Buzzard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lylord","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Tinoco-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Durbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Beiling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9521-8018","authenticated-orcid":false,"given":"Karen","family":"Minoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2287-3051","authenticated-orcid":false,"given":"Joseph P.","family":"Garay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin A.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8583-1812","authenticated-orcid":false,"given":"Michael P.","family":"Hutchens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"1411_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1136\/bmj.1.4185.427","volume":"1","author":"E Bywaters","year":"1941","unstructured":"Bywaters, E. Crush injuries with impairment of renal function. Br. Med. J. 1, 427\u2013432 (1941).","journal-title":"Br. Med. J."},{"key":"1411_CR2","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1097\/01.ASN.0000129336.09976.73","volume":"15","author":"AI Gunal","year":"2004","unstructured":"Gunal, A. I. et al. Early and vigorous fluid resuscitation prevents acute renal failure in the crush victims of catastrophic earthquakes. J. Am. Soc. Nephrology JASN 15, 1862\u20131867 (2004).","journal-title":"J. Am. Soc. Nephrology JASN"},{"key":"1411_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0735-6757(99)90059-1","volume":"17","author":"H Tanaka","year":"1999","unstructured":"Tanaka, H. et al. Morbidity and mortality of hospitalized patients after the 1995 Hanshin-Awaji earthquake. Am. J. Emerg. Med. 17, 186\u2013191 (1999).","journal-title":"Am. J. Emerg. Med."},{"key":"1411_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000494337","volume":"48","author":"T Faulk","year":"2018","unstructured":"Faulk, T. et al. Rhabdomyolysis among critically Ill combat casualties: long-term outcomes. Am. J. Nephrol. 48, 399\u2013405 (2018).","journal-title":"Am. J. Nephrol."},{"key":"1411_CR5","doi-asserted-by":"publisher","first-page":"e2046","DOI":"10.7205\/MILMED-D-17-00119","volume":"182","author":"IJ Stewart","year":"2017","unstructured":"Stewart, I. J. et al. Hyperkalemia in combat casualties: implications for delayed evacuation. Mil. Med. 182, e2046\u2013e2051 (2017).","journal-title":"Mil. Med."},{"key":"1411_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.55460\/AW4P-UO9F","volume":"16","author":"TJ Walters","year":"2016","unstructured":"Walters, T. J. et al. Management of crush syndrome under prolonged field care. J. Spec. Oper. Med. 16, 79\u201385 (2016).","journal-title":"J. Spec. Oper. Med."},{"key":"1411_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/TA.0000000000000933","volume":"80","author":"IJ Stewart","year":"2016","unstructured":"Stewart, I. J. et al. Rhabdomyolysis among critically ill combat casualties: associations with acute kidney injury and mortality. J. Trauma Acute Care Surg. 80, 492\u2013498 (2016).","journal-title":"J. Trauma Acute Care Surg."},{"key":"1411_CR8","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1097\/TA.0000000000000607","volume":"78","author":"KD Heegard","year":"2015","unstructured":"Heegard, K. D. et al. Early acute kidney injury in military casualties. J. Trauma Acute Care Surg. 78, 988\u2013993 (2015).","journal-title":"J. Trauma Acute Care Surg."},{"key":"1411_CR9","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1097\/TA.0000000000000572","volume":"79","author":"J Elterman","year":"2015","unstructured":"Elterman, J. et al. Rhabdomyolysis and acute kidney injury in the injured war fighter. J. Trauma Acute Care Surg. 79, S171\u2013S174 (2015).","journal-title":"J. Trauma Acute Care Surg."},{"key":"1411_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/00005373-199408000-00011","volume":"37","author":"JD Knottenbelt","year":"1994","unstructured":"Knottenbelt, J. D. Traumatic rhabdomyolysis from severe beating\u2013experience of volume diuresis in 200 patients. J. Trauma 37, 214\u2013219 (1994).","journal-title":"J. Trauma"},{"key":"1411_CR11","doi-asserted-by":"publisher","first-page":"e1948","DOI":"10.7205\/MILMED-D-16-00373","volume":"182","author":"D Atias-Varon","year":"2017","unstructured":"Atias-Varon, D. et al. Rhabdomyolysis after crawling military training. Mil. Med. 182, e1948\u2013e1952 (2017).","journal-title":"Mil. Med."},{"key":"1411_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/srep10901","volume":"5","author":"T Komada","year":"2015","unstructured":"Komada, T. et al. Role of NLRP3 inflammasomes for rhabdomyolysis-induced acute kidney injury. Sci. Rep. 5, 10901 (2015).","journal-title":"Sci. Rep."},{"key":"1411_CR13","first-page":"619","volume":"60","author":"RA Zager","year":"1989","unstructured":"Zager, R. A. Studies of mechanisms and protective maneuvers in myoglobinuric acute renal injury. Lab Investig. 60, 619\u2013629 (1989).","journal-title":"Lab Investig."},{"key":"1411_CR14","doi-asserted-by":"publisher","first-page":"eadk5005","DOI":"10.1126\/scitranslmed.adk5005","volume":"16","author":"L Zhou","year":"2024","unstructured":"Zhou, L. et al. Glucocorticoids induce a maladaptive epithelial stress response to aggravate acute kidney injury. Sci. Transl. Med. 16, eadk5005 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1411_CR15","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.34067\/KID.0006372022","volume":"3","author":"C Westenfelder","year":"2022","unstructured":"Westenfelder, C. & Gooch, A. Heme protein\u2013induced acute kidney injury is caused by disruption of mitochondrial homeostasis in proximal tubular. Cells Kidney 3, 2140\u20132142 (2022).","journal-title":"Cells Kidney"},{"key":"1411_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0749-0704(03)00091-5","volume":"20","author":"DJ Malinoski","year":"2004","unstructured":"Malinoski, D. J., Slater, M. S. & Mullins, R. J. Crush injury and rhabdomyolysis. Crit. Care Clin. 20, 171\u2013192 (2004).","journal-title":"Crit. Care Clin."},{"key":"1411_CR17","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1016\/j.bbadis.2017.04.011","volume":"1863","author":"DM Burmeister","year":"2017","unstructured":"Burmeister, D. M., Gomez, B. I. & Dubick, M. A. Molecular mechanisms of trauma-induced acute kidney injury: Inflammatory and metabolic insights from animal models. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 2661\u20132671 (2017).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1411_CR18","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1681\/ASN.2020030263","volume":"32","author":"K Matsushita","year":"2021","unstructured":"Matsushita, K. et al. Cilastatin ameliorates rhabdomyolysis-induced AKI in mice. J. Am. Soc. Nephrol. 32, 2579\u20132594 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1411_CR19","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/ki.2013.392","volume":"85","author":"RTN Gibney","year":"2014","unstructured":"Gibney, R. T. N., Sever, M. S. & Vanholder, R. C. Disaster nephrology: crush injury and beyond. Kidney Int. 85, 1049\u20131057 (2014).","journal-title":"Kidney Int."},{"key":"1411_CR20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ckj\/sfv024","volume":"8","author":"MS Sever","year":"2015","unstructured":"Sever, M. S. et al. Disaster nephrology: a new concept for an old problem. Clin. Kidney J. 8, 300\u2013309 (2015).","journal-title":"Clin. Kidney J."},{"key":"1411_CR21","doi-asserted-by":"publisher","first-page":"e0039","DOI":"10.5041\/RMMJ.10039","volume":"2","author":"MS Sever","year":"2011","unstructured":"Sever, M. S. & Vanholder, R. Management of crush syndrome casualties after disasters. Rambam Maimonides Med. J. 2, e0039 (2011).","journal-title":"Rambam Maimonides Med. J."},{"key":"1411_CR22","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1001\/archinternmed.2011.122","volume":"171","author":"C Bartal","year":"2011","unstructured":"Bartal, C. et al. Crush syndrome: saving more lives in disasters: lessons learned from the early-response phase in Haiti. Arch. Intern. Med. 171, 694\u2013696 (2011).","journal-title":"Arch. Intern. Med."},{"key":"1411_CR23","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1056\/NEJMra054329","volume":"354","author":"MS Sever","year":"2006","unstructured":"Sever, M. S., Vanholder, R. & Lameire, N. Management of crush-related injuries after disasters. N. Engl. J. Med. 354, 1052\u20131063 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1411_CR24","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1097\/01.CCM.0000151065.13564.6F","volume":"33","author":"D Gonzalez","year":"2005","unstructured":"Gonzalez, D. Crush syndrome. Crit. Care Med. 33, S34\u2013S41 (2005).","journal-title":"Crit. Care Med."},{"key":"1411_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJM199003223221207","volume":"322","author":"JF Desforges","year":"1990","unstructured":"Desforges, J. F., Better, O. S. & Stein, J. H. Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N. Engl. J. Med. 322, 825\u2013829 (1990).","journal-title":"N. Engl. J. Med."},{"key":"1411_CR26","first-page":"1468","volume":"66","author":"HR Champion","year":"2009","unstructured":"Champion, H. R., Holcomb, J. B. & Young, L. A. Injuries from explosions: physics, biophysics, pathology, and required research focus. J. Trauma Inj. Infect. Crit. Care 66, 1468\u20131477 (2009).","journal-title":"J. Trauma Inj. Infect. Crit. Care"},{"key":"1411_CR27","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1515\/CCLM.2010.151","volume":"48","author":"G Cervellin","year":"2010","unstructured":"Cervellin, G., Comelli, I. & Lippi, G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin. Chem. Lab Med. 48, 749\u2013756 (2010).","journal-title":"Clin. Chem. Lab Med."},{"key":"1411_CR28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nrneph.2011.56","volume":"7","author":"OS Better","year":"2011","unstructured":"Better, O. S. & Abassi, Z. A. Early fluid resuscitation in patients with rhabdomyolysis. Nat. Rev. Nephrol. 7, 416\u2013422 (2011).","journal-title":"Nat. Rev. Nephrol."},{"key":"1411_CR29","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(11)60887-8","volume":"379","author":"SA Bartels","year":"2012","unstructured":"Bartels, S. A. & Vanrooyen, M. J. Medical complications associated with earthquakes. Lancet 379, 748\u2013757 (2012).","journal-title":"Lancet"},{"key":"1411_CR30","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1681\/ASN.2016060606","volume":"28","author":"Y Hori","year":"2017","unstructured":"Hori, Y. et al. Megalin blockade with cilastatin suppresses drug-induced nephrotoxicity. J. Am. Soc. Nephrol. 28, 1783\u20131791 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1411_CR31","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.kint.2024.07.024","volume":"106","author":"M Gonz\u00e1lez-Nicol\u00e1s","year":"2024","unstructured":"Gonz\u00e1lez-Nicol\u00e1s, M. & L\u00e1zaro, A. A new therapeutic promise for acute kidney injury. Kidney Int. 106, 560\u2013562 (2024).","journal-title":"Kidney Int."},{"key":"1411_CR32","doi-asserted-by":"publisher","first-page":"116435","DOI":"10.1016\/j.bcp.2024.116435","volume":"227","author":"E Moreno-Gordaliza","year":"2024","unstructured":"Moreno-Gordaliza, E. et al. Untargeted metabolomics analysis of serum and urine unveils the protective effect of cilastatin on altered metabolic pathways during cisplatin-induced acute kidney injury. Biochem. Pharm. 227, 116435 (2024).","journal-title":"Biochem. Pharm."},{"key":"1411_CR33","doi-asserted-by":"crossref","unstructured":"Gonzalez-Fernandez, R. et al. FKBP51, AmotL2 and IQGAP1 involvement in cilastatin prevention of cisplatin-induced tubular nephrotoxicity in rats. Cells 11, 1585 (2022).","DOI":"10.3390\/cells11091585"},{"key":"1411_CR34","doi-asserted-by":"crossref","unstructured":"Jado, J. C. et al. Nephroprotective effect of cilastatin against gentamicin-induced renal injury in vitro and in vivo without altering its bactericidal efficiency. Antioxidants 9, 821 (2020).","DOI":"10.3390\/antiox9090821"},{"key":"1411_CR35","doi-asserted-by":"publisher","first-page":"704382","DOI":"10.1155\/2015\/704382","volume":"2015","author":"B Humanes","year":"2015","unstructured":"Humanes, B. et al. Protective effects of cilastatin against vancomycin-induced nephrotoxicity. Biomed. Res. Int. 2015, 704382 (2015).","journal-title":"Biomed. Res. Int."},{"key":"1411_CR36","doi-asserted-by":"publisher","first-page":"eadk6152","DOI":"10.1126\/scitranslmed.adk6152","volume":"16","author":"M Manook","year":"2024","unstructured":"Manook, M. et al. Prolonged xenokidney graft survival in sensitized NHP recipients by expression of multiple human transgenes in a triple knockout pig. Sci. Transl. Med. 16, eadk6152 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1411_CR37","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/ajt.16930","volume":"22","author":"PM Porrett","year":"2022","unstructured":"Porrett, P. M. et al. First clinical-grade porcine kidney xenotransplant using a human decedent model. Am. J. Transpl. 22, 1037\u20131053 (2022).","journal-title":"Am. J. Transpl."},{"key":"1411_CR38","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.amjsurg.2020.02.058","volume":"219","author":"S Smith","year":"2020","unstructured":"Smith, S. et al. Aggressive treatment of acute kidney injury and hyperkalemia improves survival in a combat relevant trauma model in swine. Am. J. Surg. 219, 860\u2013864 (2020).","journal-title":"Am. J. Surg."},{"key":"1411_CR39","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.cell.2019.07.017","volume":"178","author":"SR Choudhury","year":"2019","unstructured":"Choudhury, S. R. et al. Dipeptidase-1 is an adhesion receptor for neutrophil recruitment in lungs and liver. Cell 178, 1205\u20131221 e1217 (2019).","journal-title":"Cell"},{"key":"1411_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1006\/abio.1995.1184","volume":"226","author":"SP Heywood","year":"1995","unstructured":"Heywood, S. P. & Hooper, N. M. Development and application of a fluorometric assay for mammalian membrane dipeptidase. Anal. Biochem. 226, 10\u201314 (1995).","journal-title":"Anal. Biochem."},{"key":"1411_CR41","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1021\/ac60228a014","volume":"37","author":"GR Morrison","year":"1965","unstructured":"Morrison, G. R. Fluorometric microdetermination of heme protein. Anal. Chem. 37, 1124\u20131126 (1965).","journal-title":"Anal. Chem."},{"key":"1411_CR42","unstructured":"US Food and Drug Administration. Original Approval Review For Primaxin (Imipenem-Cilastatin) Washington, D. C. 1985 [accessed January 22, 2024]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=050587."},{"key":"1411_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S0090-9556(25)07650-0","volume":"17","author":"JH Lin","year":"1989","unstructured":"Lin, J. H., Chen, I. W. & Ulm, E. H. Dose-dependent kinetics of cilastatin in laboratory animals. Drug Metab. Dispos. 17, 426\u2013432 (1989).","journal-title":"Drug Metab. Dispos."},{"key":"1411_CR44","doi-asserted-by":"publisher","first-page":"c104","DOI":"10.1159\/000102997","volume":"106","author":"MM Mafham","year":"2007","unstructured":"Mafham, M. M. et al. A practical method of measuring glomerular filtration rate by iohexol clearance using dried capillary blood spots. NephronClinical Pract. 106, c104\u2013c112 (2007).","journal-title":"NephronClinical Pract."},{"key":"1411_CR45","doi-asserted-by":"crossref","unstructured":"Luis-Lima, S. et al. A simple method to measure renal function in swine by the plasma clearance of iohexol. Int. J. Mol. Sci. 19, 232 (2018)","DOI":"10.3390\/ijms19010232"},{"key":"1411_CR46","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1076-6332(96)80191-7","volume":"3","author":"B Frennby","year":"1996","unstructured":"Frennby, B. et al. Clearance of iohexol, chromium-51-ethylenediaminetetraacetic acid, and creatinine for determining the glomerular filtration rate in pigs with normal renal function: comparison of different clearance techniques. Acad. Radio. 3, 651\u2013659 (1996).","journal-title":"Acad. Radio."},{"key":"1411_CR47","first-page":"1","volume":"182","author":"B Frennby","year":"1997","unstructured":"Frennby, B. Use of iohexol clearance to determine the glomerular filtration rate. A comparison between different clearance techniques in man and animal. Scand. J. Urol. Nephrol. Suppl. 182, 1\u201363 (1997).","journal-title":"Scand. J. Urol. Nephrol. Suppl."},{"key":"1411_CR48","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1152\/jappl.1998.84.6.2154","volume":"84","author":"C Sturgeon","year":"1998","unstructured":"Sturgeon, C., Sam, A. D. 2nd & Law, W. R. Rapid determination of glomerular filtration rate by single-bolus inulin: a comparison of estimation analyses. J. Appl. Physiol. 84, 2154\u20132162 (1998).","journal-title":"J. Appl. Physiol."},{"key":"1411_CR49","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s00134-025-08035-4","volume":"51","author":"M Ostermann","year":"2025","unstructured":"Ostermann, M. et al. State of the art: renal recovery after AKI\u2014from basic science to clinical practice. Intensive Care Med. 51, 1490\u20131507 (2025).","journal-title":"Intensive Care Med."},{"key":"1411_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrneph.2017.2","volume":"13","author":"LS Chawla","year":"2017","unstructured":"Chawla, L. S. et al. Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup. Nat. Rev. Nephrol. 13, 241\u2013257 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"1411_CR51","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.ekir.2024.01.034","volume":"9","author":"SK Jensen","year":"2024","unstructured":"Jensen, S. K. et al. Acute kidney injury duration and 20-year risks of CKD and cardiovascular disease. Kidney Int. Rep. 9, 817\u2013829 (2024).","journal-title":"Kidney Int. Rep."},{"key":"1411_CR52","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2215\/CJN.06480612","volume":"8","author":"N Pannu","year":"2013","unstructured":"Pannu, N. et al. Association between AKI, recovery of renal function, and long-term outcomes after hospital discharge. Clin. J. Am. Soc. Nephrol. 8, 194\u2013202 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1411_CR53","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40620-025-02220-w","volume":"38","author":"D Patschan","year":"2025","unstructured":"Patschan, D. et al. Recovery of kidney function in acute kidney injury. J. Nephrol. 38, 445\u2013456 (2025).","journal-title":"J. Nephrol."},{"key":"1411_CR54","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1164\/rccm.201604-0799OC","volume":"195","author":"JA Kellum","year":"2017","unstructured":"Kellum, J. A. et al. Recovery after acute kidney injury. Am. J. Respir. Crit. Care Med. 195, 784\u2013791 (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1411_CR55","doi-asserted-by":"crossref","unstructured":"Ozrazgat-Baslanti, T. et al. Association of persistent acute kidney injury and renal recovery with mortality in hospitalised patients. BMJ Health Care Inform. 28, e100458 (2021).","DOI":"10.1136\/bmjhci-2021-100458"},{"key":"1411_CR56","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1309\/9AQ62FR265ER3E2W","volume":"123","author":"Z Chen-Levy","year":"2005","unstructured":"Chen-Levy, Z. et al. Factors affecting urinary myoglobin stability in vitro. Am. J. Clin. Pathol. 123, 432\u2013438 (2005).","journal-title":"Am. J. Clin. Pathol."},{"key":"1411_CR57","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3343\/alm.2023.0427","volume":"44","author":"JJH Hunsaker","year":"2024","unstructured":"Hunsaker, J. J. H. et al. Detection of a high-dose hook effect and evaluation of dilutions of urine myoglobin specimens using a serum myoglobin assay. Ann. Lab Med. 44, 367\u2013370 (2024).","journal-title":"Ann. Lab Med."},{"key":"1411_CR58","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41581-022-00585-w","volume":"18","author":"A Tong","year":"2022","unstructured":"Tong, A. et al. Patient-centred clinical trial design. Nat. Rev. Nephrol. 18, 514\u2013523 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1411_CR59","doi-asserted-by":"publisher","first-page":"e000836","DOI":"10.1136\/tsaco-2021-000836","volume":"7","author":"L Kodadek","year":"2022","unstructured":"Kodadek, L. et al. Rhabdomyolysis: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document. Trauma Surg. Acute Care Open 7, e000836 (2022).","journal-title":"Trauma Surg. Acute Care Open"},{"key":"1411_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1314-5","volume":"20","author":"LO Chavez","year":"2016","unstructured":"Chavez, L. O. et al. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit. Care 20, 135 (2016).","journal-title":"Crit. Care"},{"key":"1411_CR61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ekir.2022.09.026","volume":"8","author":"JF Hebert","year":"2023","unstructured":"Hebert, J. F. et al. Molecular mechanisms of rhabdomyolysis-induced kidney injury: from bench to bedside. Kidney Int. Rep. 8, 17\u201329 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1411_CR62","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1073\/pnas.0910174107","volume":"107","author":"O Boutaud","year":"2010","unstructured":"Boutaud, O. et al. Acetaminophen inhibits hemoprotein-catalyzed lipid peroxidation and attenuates rhabdomyolysis-induced renal failure. Proc. Natl. Acad. Sci. USA 107, 2699\u20132704 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1411_CR63","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000365851","volume":"128","author":"JH Kim","year":"2014","unstructured":"Kim, J. H. et al. Macrophage depletion ameliorates glycerol-induced acute kidney injury in mice. Nephron Exp. Nephrol. 128, 21\u201329 (2014).","journal-title":"Nephron Exp. Nephrol."},{"key":"1411_CR64","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1681\/ASN.2014040320","volume":"26","author":"J Belliere","year":"2015","unstructured":"Belliere, J. et al. Specific macrophage subtypes influence the progression of rhabdomyolysis-induced kidney injury. J. Am. Soc. Nephrol. 26, 1363\u20131377 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1411_CR65","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1093\/ndt\/gfp659","volume":"25","author":"JH Kim","year":"2010","unstructured":"Kim, J. H. et al. N-acetylcysteine attenuates glycerol-induced acute kidney injury by regulating MAPKs and Bcl-2 family proteins. Nephrol. Dial. Transpl. 25, 1435\u20131443 (2010).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1411_CR66","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1159\/000484233","volume":"43","author":"X Chen","year":"2017","unstructured":"Chen, X. et al. Curcumin-loaded nanoparticles protect against rhabdomyolysis-induced acute kidney injury. Cell Physiol. Biochem. 43, 2143\u20132154 (2017).","journal-title":"Cell Physiol. Biochem."},{"key":"1411_CR67","doi-asserted-by":"crossref","unstructured":"Wu, J. et al. Effect of curcumin on glycerol-induced acute kidney injury in rats. Sci. Rep. 7, 10114 (2017).","DOI":"10.1038\/s41598-017-10693-4"},{"key":"1411_CR68","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1039\/D4NA00334A","volume":"6","author":"Y Chen","year":"2024","unstructured":"Chen, Y. & Hou, S. Targeted treatment of rat AKI induced by rhabdomyolysis using BMSC derived magnetic exosomes and its mechanism. Nanoscale Adv. 6, 4180\u20134195 (2024).","journal-title":"Nanoscale Adv."},{"key":"1411_CR69","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/scrt497","volume":"5","author":"MM Duffy","year":"2014","unstructured":"Duffy, M. M. & Griffin, M. D. Back from the brink: a mesenchymal stem cell infusion rescues kidney function in acute experimental rhabdomyolysis. Stem Cell Res. Ther. 5, 109 (2014).","journal-title":"Stem Cell Res. Ther."},{"key":"1411_CR70","doi-asserted-by":"publisher","first-page":"e0183350","DOI":"10.1371\/journal.pone.0183350","volume":"12","author":"C Thongprayoon","year":"2017","unstructured":"Thongprayoon, C. et al. The association between renal recovery after acute kidney injury and long-term mortality after transcatheter aortic valve replacement. PLoS ONE 12, e0183350 (2017).","journal-title":"PLoS ONE"},{"key":"1411_CR71","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/ckj\/sfaa130","volume":"14","author":"J Gameiro","year":"2021","unstructured":"Gameiro, J. et al. Acute kidney disease and long-term outcomes in critically ill acute kidney injury patients with sepsis: a cohort analysis. Clin. Kidney J. 14, 1379\u20131387 (2021).","journal-title":"Clin. Kidney J."},{"key":"1411_CR72","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/jac\/18.Supplement_E.79","volume":"18","author":"GL Drusano","year":"1986","unstructured":"Drusano, G. L. An overview of the pharmacology of imipenem\/cilastatin. J. Antimicrob. Chemother. 18, 79\u201392 (1986).","journal-title":"J. Antimicrob. Chemother."},{"key":"1411_CR73","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/0006-291X(85)91335-X","volume":"131","author":"M K\u00f6ller","year":"1985","unstructured":"K\u00f6ller, M. et al. Cilastatin (MK 0791) is a potent and specific inhibitor of the renal leukotriene D4-dipeptidase. Biochem. Biophys. Res. Commun. 131, 974\u2013979 (1985).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1411_CR74","doi-asserted-by":"crossref","unstructured":"Zaballos, M. et al. Effect of cilastatin on cisplatin-induced nephrotoxicity in patients undergoing hyperthermic intraperitoneal chemotherapy. Int. J. Mol. Sci. 22, 1239 (2021).","DOI":"10.3390\/ijms22031239"},{"key":"1411_CR75","doi-asserted-by":"crossref","unstructured":"Moreno-Gordaliza, E. et al. Lipidomics reveals cisplatin-induced renal lipid alterations during acute kidney injury and their attenuation by cilastatin. Int. J. Mol. Sci. 22, 12521 (2021).","DOI":"10.3390\/ijms222212521"},{"key":"1411_CR76","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1161\/CIRCRESAHA.120.316958","volume":"127","author":"AA Gibb","year":"2020","unstructured":"Gibb, A. A., Lazaropoulos, M. P. & Elrod, J. W. Myofibroblasts and fibrosis. Circ. Res. 127, 427\u2013447 (2020).","journal-title":"Circ. Res."},{"key":"1411_CR77","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/ndt\/gfx005","volume":"32","author":"B Humanes","year":"2017","unstructured":"Humanes, B. et al. Cisplatin-induced renal inflammation is ameliorated by cilastatin nephroprotection. Nephrol. Dial. Transpl. 32, 1645\u20131655 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1411_CR78","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/ki.2012.199","volume":"82","author":"B Humanes","year":"2012","unstructured":"Humanes, B. et al. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int. 82, 652\u2013663 (2012).","journal-title":"Kidney Int."},{"key":"1411_CR79","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1124\/jpet.110.165779","volume":"334","author":"S Camano","year":"2010","unstructured":"Camano, S. et al. Cilastatin attenuates cisplatin-induced proximal tubular cell damage. J. Pharm. Exp. Ther. 334, 419\u2013429 (2010).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1411_CR80","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1093\/ndt\/gfh397","volume":"19","author":"M P\u00e9rez","year":"2004","unstructured":"P\u00e9rez, M. et al. Inhibition of brush border dipeptidase with cilastatin reduces toxic accumulation of cyclosporin A in kidney proximal tubule epithelial cells. Nephrol. Dial. Transpl. 19, 2445\u20132455 (2004).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1411_CR81","unstructured":"Munhall, A. et al. Data and Code from \u201cEfficacy of Cilastatin Sodium in a Translational Large Animal Crush Syndrome Model\u201d. In GitHub (2025)."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01411-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01411-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01411-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:02:20Z","timestamp":1777334540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01411-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1411"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01411-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7021997\/v1","asserted-by":"object"}]},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Muruve is Co-founder and CSO of Arch Biopartners Inc, owner and licensee of the following patents on cilastatin for AKI. DPEP-1 binding compositions and methods of use. Robbins S, Senger D, Rahn J, Muruve DA, Lau A. US application 15\/234,521 filed August 11, 2016, in reference to US provisional patent filed December 10, 2015. International application PCT\/IB2016\/001244 filed August 11, 2016. Use of cilastatin to reduce the nephrotoxicity of different compounds. Tejedor Jorge A, Lazaro Fernandez A, Camano Paez S, Torres Redondo AM, Lazaro Manero JA, Castilla Barba M, del Carmen De Lucas Collantes M. International application PCT\/ES2008\/070137 filed July 11, 2008. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"246"}}